View profile

FarmaKology-Gene Therapy Could Treat Pitt-Hopkins Syndrome



May 12 · Issue #103 · View online

FarmaKology is a newsletter that brings you the latest news, research, job opportunities in the Pharma world, and much more! If you would like to be featured in the newsletter, sponsor an issue, or need anything, please feel free to get in touch with me at "".

Would you like to submit an article, some interesting news, or get your startup featured? Send whatever you have to, and happy to have you featured on our newsletter (+15K Subscribers )!

Novo Banking
Novo Banking
Today's Company
MOMA Therapeutics
MOMA Therapeutics
MOMA Therapeutics
MOMA Therapeutics are on a mission to unlock molecular machines by understanding and respecting their complexities. We’ll be working incredibly hard to discover their untapped potential because we believe they are the key to delivering the next generation of precision medicines. We are unapologetically scientific, and we know this will help us achieve our mission to get new medicines to people in need. We’ve removed the bureaucracy and believe having a teammate’s back is critical to our success. You see, MOMA isn’t your typical biotech company. We are drug discovery professionals, industry specialists and scientific experts. More importantly, we’re collectively unstoppable.
Eli Lilly and Company and Incyte  announced today the U.S. Food and Drug Administration  has approved OLUMIANT® (baricitinib) for the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) with a recommended dose of 4-mg once daily for 14 days or until hospital discharge, whichever comes first.
 Strategikon Pharma announced today the release of Clinical Maestro® SOURCE version 3.0. An innovative solution that addresses the clinical RFP outsourcing process, SOURCE replaces outdated Excel-based workbooks with a powerful SaaS solution, designed by the world’s leading experts in clinical outsourcing, our biopharmaceutical customers.
 Regulus Therapeutics Inc., a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs , today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) Application for RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD), enabling the Company to initiate its planned Phase 1 clinical study of RGLS8529 in healthy volunteers.
PrecisionLife Limited, a global techbio company using its deep insights into disease biology and patient stratification to drive precision medicine in chronic diseases, is pleased to announce a partnership with Sano Genetics, a genetic research platform enabling patients to participate in ethical research projects, to advance understanding of the long-term effects of coronavirus infection (long COVID).
Research & Study
Earth911 Podcast: Desert Harvest Debuts Smart, Refillable Medicine Packaging
Job Opportunities
Upcoming Webinar & Event
Can Mark Cuban’s Low-Cost Drug Company Disrupt the Pharma Industry? | WSJ
Did you enjoy this issue?
In order to unsubscribe, click here.
If you were forwarded this newsletter and you like it, you can subscribe here.
Powered by Revue